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Abstract: Trichosporon spp. are yeast-like microorganisms responsible for skin, urinary,
pulmonary, or bloodstream infections. Due to intrinsic resistance to echinocandins, poor
susceptibility to polyenes, and preferred occurrence in immunocompromised patients, such
infections are often of poor prognosis. Yet no consensual therapeutic guidelines are presently
available. Several clinical cases of Trichosporon infections have been successfully treated
with azole therapy, including voriconazole which appeared frequently effective against
Trichosporon both in vitro and in vivo. However, the low efﬁcacy associated with some
Trichosporon genotypes, complex pharmacokinetics, and the side effects of voriconazole
represent limitations for its use and has prompted a search for other therapeutic options.
Here, we report a case of T. asahii fungemia in a patient with B-cell acute lymphoblastic
leukemia which was successfully treated with isavuconazole consecutive to stopping vor-
iconazole therapy due to severe side effects. This observation suggests that isavuconazole
with a similar spectrum to voriconazole, fewer pharmacology interactions, and side effects
may be considered as a valuable therapeutic option against Trichosporon infections.
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Case
Trichosporon species are a common cause of fungemia after Candida species in
patients with hematologic malignancies. Among all species, Trichosporon asahii is
the most frequently implicated. Several fatal cases of Trichosporon asahii infec-
tions have been reported, and early use of an appropriate antifungal appears
essential for survival. While Trichosporon spp. exhibits intrinsic resistance to
echinocandins and amphotericin B, azoles appear to be the most constantly effec-
tive agents, and voriconazole has been successfully used in clinical cases although
no well-documented consensus guidelines are presently available.1–3 Here, we
report a case of a T.asahii infection which was successfully treated with isavuco-
nazole in a patient suffering from hematologic malignancies.
A 66-year-old man of 76 kg was hospitalized in June 2018 with a recurrence of
acute lymphoid leukemia. This patient was initially diagnosed with an IgG-kappa
type multiple myeloma in 2008. Treatment was based on bortezomib-dexametha-
sone in association with dorso-lumbar D9-L1 radiotherapy and melphalan® 200
autologous stem cell transplant followed by 33 cycles of lenalidomide maintenance
therapy (IFM-2005 clinical trial). Complete remission of myeloma was obtained
with this scheme. In March 2015, an acute biphenotypic monosomy 7 and FLT3
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negative leukemia was diagnosed and treated by che-
motherapy. In February 2018, magnetic resonance imaging
revealed hemochromatosis following multiple transfu-
sions. In June 2018, the patient had pancytopenia and a
diagnosis of acute pro-B lymphoblastic leukemia was
established. The patient was treated with blinatumomab,
a bi-speciﬁc anti-CD3 and anti-CD19 monoclonal anti-
body. Due to febrile neutropenia, a large spectrum of
antibiotics was initiated on June 26th, 2018. Empiric cas-
pofungin therapy was started on July 6th due to prolonged
febrile neutropenia with suspicion of invasive fungal
infection. However, fungemia occurred on July 13th.
T.asahii was identiﬁed by mass spectrometry (maldi bio-
typer, Bruker) from blood culture. At this date, on July
13th, the patient had leucopenia (0.3 G/L). Minimal inhi-
bitory concentrations (MICs) for T. asahii isolates were
determined by E test (Table 1). On July 18th, based on
obtained MICs, a combined voriconazole (IV: 6 mg/kg
every 12 hrs for 1 day and then, 4 mg/kg every 12 hrs) +
amphotericin B therapy (Ambisome: liposomal form 3 mg/
kg/day) was started and blinatumomab therapy was
stopped. Consecutively to stopping blinatumomab therapy,
leucocyte concentration gradually increased from: 0.3 G/L,
2 G/L (polymorphonuclear neutrophils: 1.5 G/L), 2.8 G/L
(polymorphonuclear neutrophils: 2.2 G/L), 4.5–5 G/L and
ﬁnally 10.3 G/L on July 18th, August 1st, August 3rd,
August 7th to 16th and August 20th, respectively. Two
days consecutively to voriconazole introduction, on July
20th, voriconazole plasma concentration was 4.9 µg/mL,
increasing to 6.5 µg/mL on July 26th (N: 1–5µg/mL).
Consecutively to this dosage and due to neurological
adverse effects, voriconazole dose was decreased from 4
mg/kg to 2 mg/kg every 12 hrs. Four days later, on July
30th voriconazole plasma concentration was within the
normal range at 1.1 µg/mL (N: 1–5 µg/ml). On August
1st, the patient had grade III neurological toxicity with
persistent invalidating hallucinations and voriconazole
therapy was discontinued. Within two days of liposomal
amphotericin B monotherapy, erythematous skin lesions
appeared on the patient’s right thigh and disseminated in
a few days (biopsy conﬁrmed T. asahii infection) even
with leucocyte concentrations ranging between 2.8 and 5
G/L. On August 13th, based on MIC results, isavucona-
zole (IV 200 mg twice a day) was added to liposomal
amphotericin B therapy. Two days later, the infection
declined with regression of skin lesions and culture-nega-
tive results. Isavuconazole (IV) was then used at 200 mg a
day for 2 weeks and then, orally at the same dose for 3
months (Figure 1). Finally, the fungemia was successfully
treated with an isavuconazole-based therapy. Eleven
months later (to date with the current report), the patient
is still in complete remission from his underlying
pathology.
In this reported case, we observed both the inefﬁcacy of
amphotericin B-based therapy and successful treatment with
isavuconazole. Immune restoration probably potentiated the
efﬁcacy of isavuconazole. However, it is difﬁcult to attribute
recovery to immune restoration alone since the patient had
leucocytes ranging from 4.5 to 5 G/L for 6 days before
isavuconazole initiation and infection was out of control. In
this patient, several previously identiﬁed conditions promot-
ing Trichosporon infection were present. In the present case,
immunodepression was associated with malignant hemopa-
thies, and the additional role of anti-CD3 and anti-CD19
blinatumomab therapy for the treatment of acute lymphoid
leukemia requires further investigation. Moreover, among
Table 1 Sequential susceptibilities of Trichosporon asahii isolates to antifungal agents. Susceptibilities were estimated based on Candida
albicans EUCAST breakpoints version 9.0 and provided as “indicative” to clinicians in absence of available breakpoints
Tested antifungal
agent
Isolate 1a Isolate 2#
Minimal inhibitory concentrations
(mg/L)
Susceptibility Minimal inhibitory concentrations
(mg/L)
Susceptibility
Amphotericin B 0.75 Susceptible 1.5 Intermediate
Voriconazole 0.023 Susceptible 0.023 Susceptible
Isavuconazole 0.023 Susceptible 0.047 Susceptible
Flucytosine 32 Resistant 32 Resistant
Anidulafungin 32 Resistant 32 Resistant
Itraconazole 0.5 Resistant 1.0 Resistant
Posaconazole 0.094 Resistant 0.094 Resistant
Notes: aIsolate 1 was obtained from blood culture 7 days after initiation of empiric caspofungin treatment (one month before isavuconazole therapy). Isolate 2 was obtained
from cutaneous biopsy the day voriconazole therapy was stopped (12 days before isavuconazole therapy).
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risk factors our patient presented hemochromatosis. Indeed,
in 2010, Shih-Ta Shang et al described Trichosporon funge-
mia in an immunocompetent patient with hemochromatosis.4
They hypothesized that iron overload decreased T-cell immu-
nity, natural killer cell, and neutrophil activities and mono-
cyte phagocytosis. Additionally, our patient had a vascular
catheter that was removed after Trichosporon infection diag-
nosis and was suspected as the source of fungemia.
No consensus guidelines are currently available for
the treatment of Trichosporon infections even if vorico-
nazole is presented as a preferred therapy.3 Trichosporon
exhibits natural resistance to echinocandins and incon-
stant sensitivity to amphotericin B according to species.
The azole class of antifungals is the most efﬁcient for
the treatment of Trichosporon infections, and several
cases of Trichosporon infection have been treated with
voriconazole often associated with amphotericin B.2
Voriconazole, however, may interact with several other
pharmaceutical agents. In additon, high intra- and inter-
individual pharmacokinetic variability is well estab-
lished and can easily cause over- or underdosing.
Consequently, many side effects of voriconazole therapy
have been observed such as hallucinations which led to
treatment discontinuation in our case. These side effects
require a search for alternative therapeutic options.
Isavuconazole has exhibited an excellent in vitro activity
against Trichosporon.5 In the present clinical case, vor-
iconazole, used in ﬁrst intention with amphotericin B,
was discontinued due to side effects. Isavuconazole
administration resulted in improved skin lesions and
ﬁnally fungemia was controlled in absence of side
effects. This observation suggests that isavuconazole
with fewer side effects and similar efﬁciency against
Trichosporon spp. compared with voriconazole should
be considered as a valuable alternative to voriconazole
in Trichosporon infections.
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